Elevated serum levels of C5a, the most potent C anaphylatoxin, have also been reported in severe COVID-19 patients, whereas circulating C5a levels in patients with mild manifestations are similar to those of the healthy controls (62). The gene discussed is C5; the disease is COVID-19.